3.1. IL-22 overexpression or Vit D supplementation does not
protect mice from weight loss
In this project, mucositis was induced by intraperitoneal injections of
methotrexate on days -1 and 0. IL-22 overexpression group received IL-22
plasmids via hydrodynamic gene delivery on day -2 as previously
described.15 In our previous studies such injections
were shown to result in durable systemic IL-22 expression compared with
costly recombinant protein injections.19 Vit D
injection was initiated on day -5 and mice received daily injections
until termination of the experiment. To assess the impact of Vit D
injections and IL-22 overexpression weight loss was recorded daily (Fig
1). Either treatment did not affect wasting disease post methotrexate
administration suggesting that these treatments may not have impacted
circulatory factors contributing to weight loss.